In order to gain access to further scientific and clinical expertise for the continued development of AP1189, SynAct Parma has established a Scientific council.
The Scientific council represents significant pharmacological and clinical expertise within the field of melanocortin receptors and the pharmacological aspects of inflammation healing, as well as leading clinical expertise in the field of rheumatology, with particular focus on rheumatoid arthritis.
Professor of Immunology and Head of the Center for Advanced and Innovative Therapies of the Federal University of Minas Gerais (UFMG) in Brazil. UFMG is one of the leading Universities of Latin America with a long standing tradition of work in Tropical medicine and other infectious diseases.
Professor Teixeira has published more than 680 scientific articles (PubMed) and has been cited over 39,000 times (Google Scholar). Professor Teixeira is a member of the Brazilian Academy of sciences, the World Academy of Sciences (TWAS) and a Fellow of the British Pharmacological Society. He is currently Secretary of the Immunopharmacology committee of the International Union of Basic and Clinical Pharmacology (IUPHAR) , Head of the Immunotherapy committee of the International Union of Immunological Societies (IUIS) and Secretary of the International Association of Inflammation Societies (IAIS).
Professor Teixeira has done pioneering work in defining the relevance of specialized pro-resolution mediators in models of inflammation in vivo and defining the relevance of these molecules in the context of infectious diseases. His laboratory has described several mediators with defined pro-resolving activity, including angiotensin 1-7, plasmin/plasminogen and short-chain fatty acids.
Since 2020, SynAct Pharma has had a collaboration agreement with Professor Teixeira’s laboratory to investigate the effecgs of SynAct Pharma’s AP1189 molecule in the context of COVID-19.
Professor of immunopharmacology and dean of science (Dean of Research) at Barts and London School of Medicine. Prior to being appointed Scientific Dean, Professor Perretti was the co-director of the William Harvey Research Institute, one of the world’s leading pharmacological research institutions focusing on basic and translational pharmacology.
Professor Perretti has published more than 300 scientific articles and has been cited over 17,000 times. Professor Perretti is a Fellow of the British Pharmacological Society. Professor Perretti is a pioneer in understanding the role of specialized pro-resolution mediators in inflammatory processes. His laboratory is a leader in understanding the anti-inflammatory effects of the melanocortin system and has identified the melanocortin type 3 receptor as a potential target for novel innovative drug development.
Since 2012, SynAct Pharma has had a collaboration agreement with Professor Perretti’s laboratory and essential parts of the understanding of the mechanism of action of SynAct Pharma’s AP1189 molecule have been created in this collaboration.